We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 16, 2021

Evaluation of Dual vs Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

JACC: Cardiovascular interventions


Additional Info

JACC: Cardiovascular interventions
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
JACC Cardiovasc Interv 2021 Apr 12;14(7)768-780, BE Peterson, DL Bhatt, P Gabriel Steg, J Oldgren, M Maeng, U Zeymer, S Halvorsen, SH Hohnloser, GYH Lip, T Kimura, M Nordaby, C Miede, E Kleine, JM Ten Berg, CP Cannon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading